LLAJA OBISPO M. A.

Last name: LLAJA OBISPO M. A.

2022 (v1)

Publication

Metadata-only

IMMUNE TUMOR MICROENVIRONMENT (I-TME) ANALYSES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) TREATED WITH SECOND LINE NIVOLUMAB: RESULTS FROM THE MEET-URO 18 STUDY

Rebuzzi S. E. Rescigno P. Signori A.

No description

Uploaded on: February 13, 2024
2023 (v1)

Publication

Metadata-only

A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score

Fornarini G. Rebuzzi S. E. Buti S.

BACKGROUND: The current prognostic models for patients with advanced urinary tract cancers were developed and validated in the chemotherapy setting. As immunotherapy has become the backbone of novel treatments, updated prognostic scores are needed. METHODS: A comprehensive analysis of inflammatory indexes from peripheral blood and clinical...

Uploaded on: February 4, 2024
2022 (v1)

Publication

Metadata-only

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis

Rebuzzi S. E. Signori A. Stellato M.

Background: Treatment choice for metastatic renal cell carcinoma (mRCC) patients is still based on baseline clinical and laboratory factors. Methods: By a pre-specified analysis of the Meet-URO 15 multicentric retrospective study enrolling 571 pretreated mRCC patients receiving nivolumab, baseline and early dynamic variations (Δ) of neutrophil,...

Uploaded on: February 11, 2024

LLAJA OBISPO M. A.

Recent uploads